Correlation between the Rivaroxaban concentration and bleeding events in patients with non-valvular atrial fibrillation
10.3760/cma.j.issn.0254-9026.2020.05.004
- VernacularTitle:利伐沙班的药物浓度与非瓣膜性心房颤动患者出血事件的相关性
- Author:
Yan WANG
1
;
Xuyang MENG
;
Chenguang YANG
;
Li YU
;
Jing REN
;
Fang WANG
Author Information
1. 北京医院心血管内科 国家老年医学中心 中国医学科学院老年医学研究院 100730
- From:
Chinese Journal of Geriatrics
2020;39(5):501-504
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the correlation between the Rivaroxaban concentration and bleeding events in patients with nonvalvular atrial fibrillation(NVAF).Methods:This was a retrospective study.According to the inclusion and exclusion criteria, 369 patients with NVAF taking Rivaroxaban admitted to Beijing Hospital or Tianjin Medical University General Hospital from January 2018 to June 2019 were enrolled.Clinical data including sex, height, weight, liver and kidney function, drug valley concentrations and peak concentrations, doses, CHADS2 scores and bleeding events after 6 months of medication were recorded.Results:The average drug valley concentration was (44.92±38.39) mg/L, the average drug peak concentration was (226.96±139.34) mg/L, and the average CHADS2 score was (2.8±1.2). Among the 369 patients, 22 had bleeding events.The peak drug concentration and valley drug concentration were similar between those with or without bleeding events( P=0.324 and 0.960, respectively). With the increase of age, the peak drug concentration and valley drug concentration were significantly elevated(all P<0.001). In addition, compared with those without bleeding events, patients with bleeding events had a significantly higher average valley concentration( P=0.009), valley/dose ratio( P=0.001), peak/dose ratio( P=0.028)and similar peak drug concentration( P=0.360). Conclusions:Age affects the peak and valley drug concentration of Rivaroxaban, especially for the elderly, who should be given appropriately reduced doses.Monitoring the peak and valley drug concentration is of great significance for patients at high-risk for bleeding.
